Daily Stock Ratings & Price Targets
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $764 | ― | 11.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $625→$700 | ― | 18.50% | Assigned | ||||
 | Insmed | BUY $160 | ― | -1.80% | Reiterated | Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA), HCA Healthcare (NYSE: HCA) and Insmed (NASDAQ: INSM) | |||
 | Pulse Biosciences | BUY $32 | ― | -0.70% | Initiated | Pulse Biosciences initiated with a Buy at Canaccord | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $17→$14 | ― | 11.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $21 | ― | 18.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $260 | ― | 10.60% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $25→$19 | ― | 18.50% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY ― | ― | 0.50% | Reiterated | ||||
 | AbSci | BUY $12 | ― | -2.30% | Initiated | Absci initiated with an Outperform at Leerink | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $750 | ― | 11.20% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $520→$750 | ― | 18.90% | Reiterated | ||||
| Ulta Beauty | HOLD $600→$560 | ― | 0.00% | Reiterated | Ulta Beauty price target lowered to $560 from $600 at Citi | |||
| Veeva Systems | BUY $285→$235 | ― | -20.20% | Reiterated | Veeva price target lowered to $235 from $285 at Piper Sandler | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $21→$18 | ― | 18.90% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $7→$6 | ― | 3.80% | Reiterated | ||||
| Petco Health and Wellness Company | HOLD $4→$3.25 | ― | 0.00% | Reiterated | Petco price target lowered to $3.25 from $4 at Citi | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $6 | ― | 13.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $4 | ― | 13.50% | Reiterated | ||||
 | Wingstop | BUY $293→$264 | ― | -0.10% | Reiterated | Analysts Conflicted on These Consumer Cyclical Names: Macy's (NYSE: M) and Wingstop (NASDAQ: WING) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $8 | ― | 12.20% | Reiterated | ||||
 | Global Payments | BUY $105 | ― | -8.40% | Reiterated | Wells Fargo sees pullback in Global Payments shares as 'overdone' | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $610→$690 | ― | 6.10% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $540 | ― | 12.00% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $485→$502 | ― | 25.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $435→$460 | ― | 0.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $205→$215 | ― | 4.80% | Reiterated | ||||
| Roku | BUY $150→$170 | ― | -6.00% | Reiterated | Morgan Stanley Remains a Buy on Roku (ROKU) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $81→$90 | ― | 14.30% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $72→$74 | ― | 0.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $6→$7 | ― | 8.40% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $119 | ― | 0.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $387 | ― | 6.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $34 | ― | 3.70% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $13 | ― | 2.40% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $30 | ― | 2.40% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $18 | ― | 2.40% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $125 | ― | 2.40% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $3 | ― | 2.70% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $115 | ― | 10.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $545 | ― | 60.70% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $10 | ― | 0.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $475→$780 | ― | 13.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $400→$675 | ― | 12.10% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $590 | ― | 7.70% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $450→$530 | ― | 31.60% | Reiterated | ||||
| Resmed | BUY $320 | ― | -5.30% | Reiterated | Bank of America Securities Sticks to Its Buy Rating for Resmed (RMD) | |||
| Accenture | BUY $275→$248 | ― | -8.40% | Assigned | Accenture (ACN) Receives a Buy from Wells Fargo | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $241 | ― | 13.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $245→$235 | ― | 1.90% | Assigned |
Rows:
